Noteworthy Monday Option Activity: CORT, CWH, HELE Dividendchannel.com - DVND - Mon Aug 3, 7:35PM CDT Dividendchannel.com - DVND - Mon Aug 3, 7:35PM CDT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Corcept Therapeutics Inc , where a total of 6,472 contracts have traded so far, representing...
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call GlobeNewswire - Tue Jul 28, 3:05PM CDT CMTX - Tue Jul 28, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 4, 2020. The company will also host a conference...
Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing's Syndrome of Adrenal Origin GlobeNewswire - Tue Jul 28, 7:30AM CDT CMTX - Tue Jul 28, 7:30AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...
Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer GlobeNewswire - Thu Jul 23, 7:33AM CDT CMTX - Thu Jul 23, 7:33AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...
Clinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer Patients PR Newswire - PRF - Tue Jun 23, 7:45AM CDT CMTX - Tue Jun 23, 7:45AM CDT
, /PRNewswire/ -- Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT...
Corcept Therapeutics to Present Data at the American Association of Cancer Research Annual Meeting GlobeNewswire - Mon Jun 15, 7:30AM CDT CMTX - Mon Jun 15, 7:30AM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...
Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report? Zacks Equity Research - Zacks Investment Research - Wed Jun 3, 10:30AM CDT Zacks Equity Research - ZACKS - Wed Jun 3, 10:30AM CDT
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year? Zacks Equity Research - Zacks Investment Research - Wed Jun 3, 10:30AM CDT Zacks Equity Research - ZACKS - Wed Jun 3, 10:30AM CDT
Is (CORT) Outperforming Other Medical Stocks This Year?
Corcept Therapeutics to Present Data at the American Society of Clinical Oncology Annual Meeting GlobeNewswire - Thu May 14, 3:05PM CDT CMTX - Thu May 14, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y Zacks Equity Research - Zacks Investment Research - Tue May 5, 1:50PM CDT Zacks Equity Research - ZACKS - Tue May 5, 1:50PM CDT
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates Zacks Equity Research - Zacks Investment Research - Mon May 4, 6:05PM CDT Zacks Equity Research - ZACKS - Mon May 4, 6:05PM CDT
Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Corcept: 1Q Earnings Snapshot APAI - Mon May 4, 4:54PM CDT APAI - Mon May 4, 4:54PM CDT
MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Monday reported first-quarter net income of $30.1 million.
Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update GlobeNewswire - Mon May 4, 3:07PM CDT CMTX - Mon May 4, 3:07PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...
Cushing's Syndrome Pipeline Insight, 2020 Featuring Novartis Pharmaceuticals, Cortendo AB, Corcept Therapeutics and HRA Pharma - ResearchAndMarkets.com BusinessWire - Fri May 1, 11:31AM CDT CMTX - Fri May 1, 11:31AM CDT
The "Cushing's Syndrome Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call GlobeNewswire - Mon Apr 27, 3:05PM CDT CMTX - Mon Apr 27, 3:05PM CDT
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 4, 2020. The company will also host a conference call...
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice Zacks Equity Research - Zacks Investment Research - Mon Apr 27, 11:00AM CDT Zacks Equity Research - ZACKS - Mon Apr 27, 11:00AM CDT
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Growth ETFs & Stocks Set to Flourish in Spring Sweta Killa - Zacks Investment Research - Wed Apr 15, 10:05AM CDT Sweta Killa - ZACKS - Wed Apr 15, 10:05AM CDT
Given the recovering sentiments, investors should reposition their portfolio for more exposure to the growth space to obtain a nice momentum play.
RedHill (RDHL) Soars: Stock Adds 9.2% in Session Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 7:44AM CDT Zacks Equity Research - ZACKS - Wed Apr 15, 7:44AM CDT
RedHill (RDHL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Corcept Therapeutics' Shares March Higher, Can It Continue? Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 7:31AM CDT Zacks Equity Research - ZACKS - Mon Apr 13, 7:31AM CDT
As of late, it has definitely been a great time to be an investor in Corcept Therapeutics.
Why You Shouldn't Bet Against Corcept Therapeutics (CORT) Stock Zacks Equity Research - Zacks Investment Research - Thu Apr 2, 8:51AM CDT Zacks Equity Research - ZACKS - Thu Apr 2, 8:51AM CDT
Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
